logo image

Enalapril+Losartan information from DrugsUpdate  

See Available Brands of Enalapril+Losartan in India

Enalapril and Losartan are angiotensin-converting enzyme II inhibitor, generally prescribed for the treatment and management of hypertension and heart failure in adults. Recent clinical studies proved that Enalapril and Losartan are also effective against proteinuria in post-diarrhoeal haemolytic uremic syndrome (D + HUS) sequelar proteinuria.

Pharmacodynamics

After oral or intravenous administration, Enalapril is deesterified into active metabolite, Enalaprilat. The metabolite effectively inhibits the angiotensin converting enzyme (ACE) that results in reduced levels of angiotensin II and aldosterone. The reduction of such hypertensive mediators results in reduced salt and BP levels with correction of fluid retention. The action of the combined drugs reverses ventricular hypertrophy and increase renal blood flow.

Pharmacokinetics

After oral administration, about 60% of the administered dose is absorbed in the GIT with a peak plasma concentration after one hour and 3-4 hours for Enalapril and enalaprilat, respectively. The protein-binding capability of enalaprilat is about 50-60%. The drug is extensively metabolized in the liver, and hydrolyzed to enalaprilat. After metabolism, the drug is mostly excreted via the urine as enalaprilat as unchanged drug. The terminal half-life of Enalapril + Losartan is about 11 hours.

Enalapril+Losartan Indications / Enalapril+Losartan Uses

No information available

Enalapril+Losartan Adverse Reactions / Enalapril+Losartan Side Effects

Enalapril + Losartan can cause serious angioedema, severe and persistent hypotension, dizziness, headache, lassitude, rashes, neutropenia, renal impairment, dry cough, taste changes, renal disorders and persistent dry cough.

Precautions

Enalapril and Losartan are contraindicated in patients with bilateral renal artery stenosis, hypersensitivity, history of angioedema, impaired renal function, hyperkalemia, hypovolemia, unilateral renal artery stenosis, hypovolemia associated hypotension and immediately before or after anaesthesia procedure.

Special Precautions

No information available

Other Drug Interactions

Enalapril and Losartan may interact with diuretics, lithium, immunosuppressive drugs, potassium-sparing diuretics, potassium supplements, probenecid, morphine, NSAIDs and other opioid analgesics.

Other Interactions

No information available

Dosage

For the treatment of Hypertension (Adults):
As an oral formulation, consider initial dose of 5 mg at bedtime. The maintenance therapy should be 10-20 mg/day, and can be increased up to 40 mg in divided dose, in renal impaired patients. The maximum daily dose should not exceed 40 mg.
For the treatment of Hypertension (Geriatrics):
Consider administration of 2.5 mg once daily.
For the treatment of Hypertension (Pediatrics):
Consider administration of 80 mcg/kg/day. The maximum daily dose should not exceed 5 mg/day.
For the treatment of heart failure (Adults):
Start with an initial dose of 2.5 mg/day with a maintenance dose of 20 mg as single or two divided doses. The maximum dose should not exceed 40 mg/day.
Intravenous
For the treatment of Hypertension (Adults)
Consider slow intravenous administration of 1.25 mg of Enalapril + Losaratan over 5 minutes. The dose can be repeated every six hours, if needed.

Food(before/after)

Enalapril + Losartan should be taken before food intake. Take the drug at least 15-30 min before meals.

List of Contraindications

Enalapril+Losartan and Pregnancy

Contraindicated in pregnancy
USFDA pregnancy category D. Enalapril + Losartan can harm the unborn fetus. Perform pregnancy tests before using Enalapril + Losartan. Use effective contraceptive mode to prevent unintended pregnancies while taking Enalapril + Losartan.

Enalapril+Losartan and Lactation

Nursing mothers should consult a physician before

Enalapril+Losartan and Children

No information available

Enalapril+Losartan and Geriatic

No information available

Enalapril+Losartan and Other Contraindications

No information available

Storage

Intravenous Injections and Oral Formulations: Store below 30°C.

Lab interference

Intravenous Injections and Oral Formulations: Store below 30°C.

© 2011-2020 DrugsUpdate.com from UPilot INC. Disclaimer | Site Map

Feedback
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to millions of Visitors instantly.